We are live on ! Find out more
EDIT icon

Editas Medicine

229 hedge funds and large institutions have $188M invested in Editas Medicine in 2024 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 68 increasing their positions, 64 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more call options, than puts

Call options by funds: $1.5M | Put options by funds: $1.14M

6% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 64

1.71% less ownership

Funds ownership: 68.57%66.86% (-1.7%)

3% less funds holding

Funds holding: 235229 (-6)

12% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 41

29% less capital invested

Capital invested by funds: $263M → $188M (-$75.6M)

Holders
229
Holders Change
-6
Holders Change %
-2.55%
% of All Funds
3.29%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
36
Increased
68
Reduced
64
Closed
41
Calls
$1.5M
Puts
$1.14M
Net Calls
+$362K
Net Calls Change
-$415K
Name Holding Trade Value Shares
Change
Change in
Stake
Point72 Asset Management
51
Point72 Asset Management
Connecticut
$366K +$467K +107,360 New
PAS
52
Point72 Asia (Singapore)
Singapore
$320K +$408K +93,789 New
Walleye Capital
53
Walleye Capital
New York
$318K +$406K +93,327 New
Squarepoint
54
Squarepoint
New York
$316K -$2.62M -601,467 -87%
Invesco
55
Invesco
Georgia
$313K +$18.6K +4,263 +5%
CAM
56
Congress Asset Management
Massachusetts
$305K -$4.09K -939 -1%
Deutsche Bank
57
Deutsche Bank
Germany
$302K +$62.4K +14,326 +19%
TI
58
Tidal Investments
Wisconsin
$293K -$137K -31,436 -27%
Thrivent Financial for Lutherans
59
Thrivent Financial for Lutherans
Minnesota
$292K
Legal & General Group
60
Legal & General Group
United Kingdom
$286K +$19K +4,371 +6%
SPA
61
Sherbrooke Park Advisers
New York
$265K +$338K +77,663 New
Cambridge Investment Research Advisors
62
Cambridge Investment Research Advisors
Iowa
$254K +$2.06K +474 +0.6%
California State Teachers Retirement System (CalSTRS)
63
California State Teachers Retirement System (CalSTRS)
California
$253K -$11.7K -2,694 -4%
DTL
64
Dynamic Technology Lab
Singapore
$240K +$307K +70,408 New
TYCC
65
Texas Yale Capital Corp
Florida
$239K
PI
66
PEAK6 Investments
Illinois
$229K -$163K -37,500 -36%
Citigroup
67
Citigroup
New York
$224K -$514 -118 -0.2%
LPL Financial
68
LPL Financial
California
$224K -$55.3K -12,699 -16%
T. Rowe Price Associates
69
T. Rowe Price Associates
Maryland
$222K +$53.8K +12,363 +24%
Marshall Wace
70
Marshall Wace
United Kingdom
$217K -$1.68M -385,394 -86%
RJFSA
71
Raymond James Financial Services Advisors
Florida
$208K -$18.3K -4,203 -6%
Ameriprise
72
Ameriprise
Minnesota
$203K +$94.8K +21,766 +58%
HSBC Holdings
73
HSBC Holdings
United Kingdom
$197K -$210K -48,143 -46%
BNP Paribas Financial Markets
74
BNP Paribas Financial Markets
France
$187K +$64.8K +14,888 +37%
PD
75
Point72 (DIFC)
United Arab Emirates
$187K +$238K +54,775 New

EDIT Hedge Fund Activity: Q3 2024 in Review

229 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q3 2024, worth a combined $188M — down 29% from $263M a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of EDIT and 36 opened new positions — a net loss of 5 holders — while 64 trimmed existing stakes and 68 added.

The largest buyer was Millennium Management, adding an estimated $3.88M. The largest seller was State Street, cutting an estimated $9.27M.

  • 229 institutional investors held Editas Medicine (EDIT) as of Q3 2024, down from 235 in Q2 2024.
  • Funds reported $188M of Editas Medicine stock for Q3 2024, down 29% quarter-over-quarter.
  • 36 funds opened new Editas Medicine positions in Q3 2024 and 41 closed out, a net change of -5 holders.
  • The largest Editas Medicine buyer in Q3 2024 was Millennium Management, an estimated $3.88M added.
  • The largest Editas Medicine seller in Q3 2024 was State Street, an estimated $9.27M sold.

Based on aggregated 13F filings for Q3 2024.